loading
Telomir Pharmaceuticals Inc stock is traded at $4.69, with a volume of 46,750. It is down -2.09% in the last 24 hours and down -4.48% over the past month. Telomir Pharmaceuticals Inc is a pioneering preclinical-stage pharmaceutical company leading the advancement of age-reversal science. The Company is focused on developing Telomir-1, a novel small molecule designed to lengthen and protect telomeres-the protective DNA end caps of chromosomes that are crucial to cellular aging. As humans and animals age, telomeres naturally shorten, with metal reactivity accelerating this process, increasing the risk of degenerative and age-related diseases. By addressing the underlying causes of aging at the cellular level, Telomir aims to tackle the root of these conditions rather than simply treating their symptoms. Telomir is conducting ongoing preclinical research into Progeria, diabetes, cancer, Alzheimer's disease, osteoarthritis, and others.
See More
Previous Close:
$4.79
Open:
$4.83
24h Volume:
46,750
Relative Volume:
0.28
Market Cap:
$139.54M
Revenue:
-
Net Income/Loss:
$-13.08M
P/E Ratio:
-10.62
EPS:
-0.4416
Net Cash Flow:
-
1W Performance:
+14.11%
1M Performance:
-4.48%
6M Performance:
+18.43%
1Y Performance:
+0.00%
1-Day Range:
Value
$4.61
$4.9417
1-Week Range:
Value
$4.1448
$5.17
52-Week Range:
Value
$3.11
$20.72

Telomir Pharmaceuticals Inc Stock (TELO) Company Profile

Name
Name
Telomir Pharmaceuticals Inc
Name
Phone
786-396-6723
Name
Address
100 SE 2ND ST, MIAMI
Name
Employee
0
Name
Twitter
Name
Next Earnings Date
2024-11-11
Name
Latest SEC Filings
Name
TELO's Discussions on Twitter

Compare TELO with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
TELO
Telomir Pharmaceuticals Inc
4.69 139.54M 0 -13.08M 0 -0.4416
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
422.00 108.68B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
681.58 74.90B 13.85B 4.65B 3.32B 40.41
Biotechnology icon
ARGX
Argen X Se Adr
640.52 38.30B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
246.27 31.76B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
111.93 26.83B 3.30B -501.07M 1.03B -2.1146

Telomir Pharmaceuticals Inc Stock (TELO) Latest News

pulisher
Jan 17, 2025

Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) Short Interest Up 58.9% in December - MarketBeat

Jan 17, 2025
pulisher
Jan 16, 2025

Telomir Pharmaceuticals, Inc.'s (NASDAQ:TELO) biggest owners are retail investors who got richer after stock soared 13% last week - Yahoo Finance

Jan 16, 2025
pulisher
Jan 16, 2025

Telomir Pharmaceuticals, Inc.'s (NASDAQ:TELO) market cap surged US$16m last week, retail investors who have a lot riding on the company were rewarded - Simply Wall St

Jan 16, 2025
pulisher
Jan 10, 2025

Barclays PLC Buys 5,367 Shares of Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) - Defense World

Jan 10, 2025
pulisher
Jan 09, 2025

Geode Capital Management LLC Has $1.53 Million Stock Position in Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) - MarketBeat

Jan 09, 2025
pulisher
Jan 09, 2025

Geode Capital Management LLC Grows Stock Holdings in Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) - Defense World

Jan 09, 2025
pulisher
Jan 08, 2025

Telomir Pharmaceuticals reports breakthrough in progeria study By Investing.com - Investing.com Nigeria

Jan 08, 2025
pulisher
Jan 07, 2025

Telomir Pharmaceuticals confirms lifespan restoration in Progeria preclinical model with Telomir-1 - MSN

Jan 07, 2025
pulisher
Jan 07, 2025

Telomir Pharmaceuticals reports breakthrough in progeria study - Investing.com

Jan 07, 2025
pulisher
Jan 07, 2025

Telomir Pharmaceuticals Confirms Lifespan Restoration and Normalization of Accelerated Aging in Preclinical Model of Progeria (A Rare Genetic Disorder Causing Rapid Aging) - AccessWire

Jan 07, 2025
pulisher
Jan 04, 2025

State Street Corp Acquires 17,967 Shares of Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) - Defense World

Jan 04, 2025
pulisher
Dec 29, 2024

Short Interest in Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) Expands By 22.9% - MarketBeat

Dec 29, 2024
pulisher
Dec 26, 2024

Telomir Pharmaceuticals Confirms Copper-Binding Capabilities of Telomir-1 and Expands Pipeline into Wilson’s Disease - Defense World

Dec 26, 2024
pulisher
Dec 26, 2024

Telomir Pharmaceuticals Expands Pipeline, Confirms Copper-Binding Potential of Telomir-1 for Wilson’s Disease - ChemAnalyst

Dec 26, 2024
pulisher
Dec 23, 2024

Telomir-1 shows promise in copper binding studies - Investing.com

Dec 23, 2024
pulisher
Dec 23, 2024

Telomir Pharmaceuticals Confirms Copper Binding Capabilities of Telomir-1 and Expands Pipeline Into Wilson's Disease - Chronicle-Tribune

Dec 23, 2024
pulisher
Dec 23, 2024

EXCLUSIVE: Telomir Pharmaceuticals Reports Potential Of Telomir-1 For Wilson's Disease - Yahoo Finance

Dec 23, 2024
pulisher
Dec 22, 2024

Telomir Pharmaceuticals appoints new accounting firm - Investing.com India

Dec 22, 2024
pulisher
Dec 17, 2024

Telomir Pharmaceuticals Raises $1 Million in Premium-Priced Stock Deal, Boosting Age-Reversal Research - Citybuzz

Dec 17, 2024
pulisher
Dec 17, 2024

Telomir Pharmaceuticals Secures $1 Million At $7 Per Share In No-Warrant, Restricted Stock Deal, Underscoring Investor Confidence With A 20% Premium Valuation - Nasdaq

Dec 17, 2024
pulisher
Dec 16, 2024

Telomir Pharmaceuticals enters into stock purchase agreement - MSN

Dec 16, 2024
pulisher
Dec 12, 2024

Telomir Pharmaceuticals secures $1 million equity funding - Investing.com

Dec 12, 2024
pulisher
Dec 12, 2024

Telomir Pharmaceuticals Raises $1 Million at $7 per Share in a No-Warrant, Restricted Common Stock Deal, Representing a 20% Premium to Closing Price - AccessWire

Dec 12, 2024
pulisher
Dec 12, 2024

Telomir Pharmaceuticals Secures Premium-Priced Funding After Breakthrough Anti-Aging Drug Results - StockTitan

Dec 12, 2024
pulisher
Dec 12, 2024

Telomir Pharmaceuticals secures $1 million in equity funding By Investing.com - Investing.com Canada

Dec 12, 2024
pulisher
Dec 11, 2024

Telomir Pharmaceuticals secures $1 million in equity funding - Investing.com

Dec 11, 2024
pulisher
Dec 11, 2024

(TELO) Technical Data - Stock Traders Daily

Dec 11, 2024
pulisher
Dec 04, 2024

Stocks In Play: Renegade Gold Inc. - Barchart

Dec 04, 2024
pulisher
Dec 04, 2024

Telomir-1 shows promise in diabetes preclinical study By Investing.com - Investing.com Nigeria

Dec 04, 2024
pulisher
Dec 03, 2024

Unifor And PPWC Target Kruger, Inc. To Begin Western Pattern Bargaining - Barchart

Dec 03, 2024
pulisher
Dec 03, 2024

Stocks In Play: Yukon Metals Corp - Barchart

Dec 03, 2024
pulisher
Dec 03, 2024

Telomir-1 shows promise in diabetes preclinical study - Investing.com India

Dec 03, 2024
pulisher
Dec 03, 2024

Deadline To Apply For A Special Ballot Approaches - Barchart

Dec 03, 2024
pulisher
Dec 03, 2024

Media AdvisoryDeputy Prime Minister's Itinerary For Wednesday, December 4, 2024 - Barchart

Dec 03, 2024
pulisher
Dec 03, 2024

AME ANNOUNCES 2024 AWARD RECIPIENTS - Barchart

Dec 03, 2024
pulisher
Dec 03, 2024

Perimeter Provides Update on Canada Postal Strike and Mailing of the Company's 2024 Annual General Meeting Materials - Barchart

Dec 03, 2024
pulisher
Dec 03, 2024

Ontario Lottery And Gaming CorporationMidDay Lottery Winning NumbersDec. 3, 2024 - Barchart

Dec 03, 2024
pulisher
Dec 03, 2024

Stocks In Play: PyroGenesis Inc. - Barchart

Dec 03, 2024
pulisher
Dec 03, 2024

Fuchs Endothelial Corneal Dystrophy Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | ProQR Therapeutics, Kowa Pharmac, Trefoil Therapeutics, Alcon Inc., Emmecell - Barchart

Dec 03, 2024
pulisher
Dec 03, 2024

Telomir Pharmaceuticals Announces Reversal of Key Type 2 Diabetes Parameters in Preclinical Study - newsbreak.com

Dec 03, 2024
pulisher
Dec 03, 2024

Telomir Pharmaceuticals' Shares Rally After Positive Results for Diabetes Treatment - MarketWatch

Dec 03, 2024
pulisher
Dec 03, 2024

Gastroesophageal Adenocarcinoma Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | AskGene Pharma, Inc., Akeso, Weill Medical College, Seagen Inc., Merck, Taiho Pharma - Barchart

Dec 03, 2024
pulisher
Dec 03, 2024

Telomir Pharmaceuticals Achieves Breakthrough in Type 2 Diabetes Treatment with Novel Age-Reversal Drug - Barchart

Dec 03, 2024
pulisher
Dec 03, 2024

Enbridge Inc. Announced 3% Quarterly Dividend Increase For 2025 - Barchart

Dec 03, 2024
pulisher
Dec 03, 2024

Telomir Pharmaceuticals Announces Reversal of Key Type 2 Diabetes Parameters in Groundbreaking Preclinical Study With Telomir-1 - AccessWire

Dec 03, 2024
pulisher
Dec 02, 2024

Telomir Pharmaceuticals reports breakthrough in diabetes study - Investing.com

Dec 02, 2024
pulisher
Dec 02, 2024

Telomir Pharmaceuticals reports breakthrough in diabetes study By Investing.com - Investing.com Canada

Dec 02, 2024
pulisher
Nov 29, 2024

Stocks In Play: Southern Energy Corp. - Barchart

Nov 29, 2024
pulisher
Nov 28, 2024

Telomir Pharmaceuticals Inc (TELO) Recovers 37.62% From Low: Are We There Yet? - Stocks Register

Nov 28, 2024
pulisher
Nov 27, 2024

Telomir Pharmaceuticals, Inc. Announces Board Changes - Marketscreener.com

Nov 27, 2024
pulisher
Nov 26, 2024

Eton PharmaSmall Cap That's Climbing - Barchart

Nov 26, 2024

Telomir Pharmaceuticals Inc Stock (TELO) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$30.75
price down icon 0.65%
$71.93
price down icon 0.75%
$19.03
price up icon 4.62%
$358.93
price down icon 2.04%
biotechnology ONC
$210.08
price up icon 2.31%
$111.93
price down icon 0.74%
Cap:     |  Volume (24h):